Researcher profile
Thomas R. Arkell
Affiliations
Organizations
Public evidence
8 connected articles
A semi-naturalistic open-label study examining the effect of prescribed medical cannabis use on simulated driving performance.2024 · Europe PMCMedical cannabis use in Australia seven years after legalisation: findings from the online Cannabis as Medicine Survey 2022-2023 (CAMS-22).2024 · Europe PMCA Semi-Naturalistic, Open-Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive Performance.2023 · PubMed Central Open AccessDriving-related behaviors, attitudes, and perceptions among Australian medical cannabis users: results from the CAMS 20 survey.2023 · PubMed Central Open AccessCannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis.2022 · Europe PMCMedical cannabis use in the Australian community following introduction of legal access: the 2018-2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18).2020 · PubMed Central Open AccessCannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.2019 · Europe PMCDetection of Δ<sup>9</sup> THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices.2019 · Europe PMC
Matched by exact identifiers only. Profile data: Corpus/OpenAlex.